Let’s focus more on regional diversity of acromegaly

Störmann, Sylvère

doi:10.21037/atm-22-3653

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 3 However, estimates on prevalence and incidence may greatly vary according to regional differences, with prevalence estimates ranging from 28 to 137 cases per million population and incidence ranging from 2 to 12 cases per million person-years. 4 …”

Section: Introductionmentioning

confidence: 99%

Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences

Chiloiro,

Appetecchia,

Bianchi

et al. 2024

DIC

View full text Add to dashboard Cite

Pasireotide-LAR is recommended as a second-line treatment for patients with acromegaly. Although the effects of pasireotide-LAR have been well characterized in clinical studies, real-practice evidence is scant, especially in the long term and within the individualization of therapy in patients with comorbidities. To provide additional insight on the individualized approach to acromegaly management, six clinical cases of complex acromegaly treated with pasireotide-LAR for more than 5 years were reported. Pasireotide-LAR allowed the normalization of insulin-like growth factor 1 (IGF1) values in all patients and reduced tumour residue volume where present. A good safety profile and long-term tolerability were also reported.

show abstract

Section: Introductionmentioning

confidence: 99%

Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences

Chiloiro,

Appetecchia,

Bianchi

et al. 2024

DIC

View full text Add to dashboard Cite

show abstract

The socioeconomic burden of acromegaly

Störmann

Cuny

2023

European Journal of Endocrinology

View full text Add to dashboard Cite

Acromegaly is a rare and insidious disease characterized by chronic excess growth hormone, leading to various morphological changes and systemic complications. Despite its low prevalence, acromegaly poses a significant socioeconomic burden on patients and healthcare systems. This review synthesizes the current state of knowledge on the psychosocial burden, disability, impact on daily life, and cost of acromegaly disease, focusing on quality of life, partnership, medical care and treatment afflictions, participation in daily activities, professional and leisure impairment, and cost of treatment for acromegaly and its comorbidities. It also examines management strategies, coping mechanisms, and interventions aimed at alleviating this burden. Comprehensive understanding of the extent of the socioeconomic burden in acromegaly is crucial to develop effective strategies to improve treatment and care. Further research is warranted to explore the myriad factors contributing to this burden, as well as the efficacy of interventions to alleviate it, ultimately enhancing the quality of life for patients with acromegaly.

show abstract

Let’s focus more on regional diversity of acromegaly

Cited by 2 publications

References 25 publications

Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences

Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences

The socioeconomic burden of acromegaly

Contact Info

Product

Resources

About